Summit Therapeutics Inc. (NASDAQ:SMMT) Receives Average Rating of “Buy” from Analysts
Shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Get Free Report) have been assigned a consensus rating of “Buy” from the eleven brokerages that are covering the firm, Marketbeat reports. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price […]
Shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Get Free Report) have been assigned a consensus rating of “Buy” from the eleven brokerages that are covering the firm, Marketbeat reports. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price […]
